Le Lézard
Classified in: Health, Business
Subjects: CXP, FVT, MAT

PharmaCann Celebrates Opening of Verilife South Philadelphia Retail Location


Verilife South Philadelphia is the second Verilife dispensary in the metro area and ninth in Pennsylvania

CHICAGO, March 6, 2024 /PRNewswire/ -- PharmaCann Inc. ("PharmaCann" or the "Company"), one of the nation's largest privately held, vertically integrated medical marijuana companies, today announced the opening of its Verilife South Philadelphia dispensary. Located at 1300 S. Christopher Columbus Boulevard, Suite 11B, in Philadelphia, Verilife South Philadelphia expands the Company's retail presence to nine retail Verilife locations statewide and 56 locations nationwide, including the Company's LivWell dispensaries.

Verilife South Philadelphia is a patient-centric medical dispensary offering exceptional service and a vast selection of affordable products, including premium flower, tinctures, vapes, topicals, and more. Verilife is dedicated to providing top-rated customer service and an unparalleled shopping experience for the medical cannabis community of South Philadelphia.

"We are beyond thrilled to open the doors of our newest Verilife location in South Philadelphia," said PharmaCann CEO Brett Novey. "For nearly a decade, the Commonwealth of Pennsylvania has fostered a thriving medical marijuana community, and we are proud to operate nine Verilife locations in Pennsylvania, each committed to putting patients first. As we open the doors of Verilife South Philadelphia on the city's scenic waterfront, we are eager to welcome new patients.

Verilife will host a grand opening event on Friday, March 15th from 9am - 2pm EST featuring a ribbon-cutting ceremony led by Meghan Sack of the Chamber of Commerce for Greater Philadelphia, followed by vendor booths, exclusive education and promotional opportunities for registered patients. For more information on Verilife's locations, patient resources, and products in Pennsylvania, please visit https://www.verilife.com/.

About PharmaCann
PharmaCann Inc. is one of the nation's largest privately held, vertically integrated marijuana companies, providing safe, reliable, and high-quality products to patients and consumers in both the medical and adult-use markets. The PharmaCann geographic footprint includes dispensaries as well as cultivation and processing operations in eight states. For more information about PharmaCann, please visit Pharmacann.com.

SOURCE PharmaCann


These press releases may also interest you

at 18:05
Reality TV Star, Mollie Pearce, Backs Campaign to Tackle Inequalities in Condition That Impacts Millions of People Globally
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
Red Door Community Raises more than $300,000 at Their Annual Luncheon Celebrating Women Working and Living with Cancer
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Easy Eats Pandemanila brand Kalihim (Philippine Bread Rolls) recalled due to undeclared egg
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
Industrial Automation Market In Life Sciences Industry size is set to grow by USD 5.06 bn from 2024-2028, growing global demand for healthcare services to boost the market growth, Technavio
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
MODULAR ATP Study of the mCRMtm System Meets Primary Safety and Efficacy Endpoints
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Investigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...

More news about Health...


News published on and distributed by: